A signal that comes from your mitochondria
MOTS-c is a short chain of amino acids encoded in mitochondrial DNA. Mitochondria are best known for producing cellular energy, but this research suggests they also send signals that influence metabolism.
That discovery made MOTS-c a research target for obesity, insulin resistance and ageing. The important caveat is that most of the treatment evidence comes from animals.
What animal studies found
The work that brought MOTS-c to wider attention was done in mice. Injected MOTS-c substantially prevented diet-induced obesity and improved insulin sensitivity.
Researchers link this to AMPK, an energy-sensing pathway that metformin also acts on. A commentary in Cell Metabolism also noted that some observations didn't fit neatly with the proposed mechanism, so the full picture is still being worked out.
What human research shows
Human studies so far mostly measure the MOTS-c your body already makes. They haven't tested whether giving it improves health.
- Exercise: human studies reported that exercise raises MOTS-c in muscle and blood for a short time.
- Age: blood levels were reported to be 11% and 21% higher in young men than in middle-aged and older men.
- Body weight: levels were about 20% lower in one group of obese boys and teenagers, but a separate adult group found no link with BMI.
These findings show association, not cause. A 2023 review described no human treatment trials and said no effective clinical method of giving MOTS-c had been developed.
What we don't know yet
- Whether injected MOTS-c produces the same effects in people as in mice
- The most effective dose and treatment length
- Long-term safety in humans
- How it compares with established weight-loss treatments
How it fits with other treatment
MOTS-c doesn't replace nutrition, resistance training or sleep. It also has far less human evidence than weight management compound, which has been tested in large clinical trials.
Medicines that lower blood sugar need particular care. Tell your doctor if you use insulin, a sulfonylurea or metformin, because low blood sugar is a possible risk.
Who should avoid it
Ambrosia's product information lists these reasons not to use MOTS-c, unless your doctor advises otherwise:
- Pregnancy or breastfeeding
- Active cancer
- Type 1 diabetes without specialist supervision
Possible side effects include injection-site reactions and symptoms of low blood sugar.
How it's prescribed
Ambrosia dispenses MOTS-c as a 60 mg cartridge in 2,4 ml, usually injected on two or three days a week. Your doctor decides your dose after reviewing your medical history. Every Ambrosia treatment requires a prescription.
This article is for educational purposes only and is not medical advice.


